Article Text

PDF

Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.
  1. N Ohguro,
  2. M Matsuda,
  3. Y Ohashi and
  4. M Fukuda
  1. Department of Ophthalmology, Osaka University Medical School, Japan.

    Abstract

    BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • Research Article
      D Coster